NMN Drug Interactions: Medications, Cancer Therapy & What We Actually Know

NMN does not currently have a long, well-established list of proven drug interactions. The more important issue is that formal interaction studies are sparse, while NMN can affect pathways and biomarkers—glucose handling, blood pressure, NAD metabolism and inflammatory responses—that may matter in people taking medication.

“No known interaction” is not the same as “proven no interaction.”

NMN drug interactions: evidence map

Medication / situation	What we know	Practical interpretation
Diabetes medicines	NMN has altered insulin sensitivity in some trials; pooled glucose effects are mostly null	Monitor glucose rather than assuming an additive effect
Blood-pressure medicines	Small pooled DBP reduction; SBP overall mostly null	Potential physiologic overlap, not a proven pharmacokinetic interaction
Chemotherapy	Preclinical pancreatic-cancer models show possible protection of tumor cells from chemotherapy	Use only with oncology-team guidance
Anticoagulants / antiplatelets	No strong NMN-specific interaction trial	Do not invent a bleeding interaction; review the entire supplement stack
Statins	No established CYP-based NMN interaction	Lipid effects are not reliably beneficial in meta-analysis
Immunosuppressants	No dedicated interaction RCT	Disease context and immune effects warrant clinician review
Other NAD precursors	Overlapping pathway exposure	No evidence that stacking improves outcomes
Resveratrol / polyphenols	Common stack, but combination benefit is preclinical	Adds another active compound and its own interaction profile

Does NMN interact with diabetes medication?

The Yoshino trial found improved muscle insulin sensitivity in postmenopausal women with prediabetes, showing that NMN can have real glucose-regulatory biology in at least one population. ^[1]

However, meta-analyses have not shown consistent reductions in fasting glucose, HbA1c or HOMA-IR across trials. ^{[2] [3]}

There is no evidence-based rule that insulin, metformin, GLP-1 drugs or other glucose-lowering therapies require a specific NMN dose adjustment. People taking them should avoid assuming that NMN is metabolically inert and monitor as clinically appropriate.

NMN and blood-pressure medication

A 2026 meta-analysis found a small pooled reduction in diastolic blood pressure, while the overall systolic effect was not significant. ^[4]

This is not evidence that NMN dangerously potentiates antihypertensives, but it does mean blood pressure is a relevant endpoint rather than something to ignore. People prone to dizziness or low pressure should evaluate the whole regimen rather than attributing symptoms automatically to one product.

NMN and chemotherapy: the interaction with the strongest reason for caution

In 2026 preclinical pancreatic-cancer experiments, NMN increased cancer-cell survival under metabolic and chemotherapy stress and reduced the effectiveness of several chemotherapies in model systems. ^[5]

This is not human proof, but the clinical stakes are high enough that active chemotherapy is not an appropriate context for unsupervised NAD-precursor experimentation. A separate mouse tumor-immunity study found antitumor macrophage effects from high-dose NMN, reinforcing that cancer effects are context-dependent rather than uniformly beneficial or harmful. ^[6]

Does NMN interact through CYP450 enzymes?

NMN is not currently supported by strong evidence as a clinically important CYP3A4, CYP2D6 or CYP2C9 inhibitor comparable to known drug-interaction compounds. Lists online that assign NMN extensive CYP interactions without direct data should be treated skeptically.

That does not eliminate other types of interaction: pharmacodynamic overlap, disease-specific effects, altered biomarker interpretation and unknowns can still matter.

NMN with anticoagulants or aspirin

There is no robust human NMN trial demonstrating a clinically important bleeding interaction. Claims that NMN “thins the blood” should not be stated as fact.

However, many people taking NMN also stack resveratrol, fisetin, omega-3s or other supplements with their own bleeding or platelet considerations. The relevant medication review is therefore often the entire stack, not NMN in isolation.

NMN with statins

Human meta-analyses do not show a consistent lipid-lowering effect from NMN. ^[7] There is no established reason to replace, reduce or discontinue statin therapy because of NMN supplementation.

NMN with other NAD boosters

A direct 2026 trial found that NMN and NR each substantially raised blood NAD+ at 1,000 mg/day. Stacking both has not been shown to provide superior clinical benefit and may simply increase cost and pathway exposure.

Similarly, adding nicotinamide, niacin or intravenous NAD+ should be treated as a separate intervention rather than an automatic “more NAD is better” strategy.

Who should ask a clinician before using NMN?

• People receiving chemotherapy or other active cancer treatment.
• People with brittle diabetes or frequent hypoglycemia.
• People with symptomatic low blood pressure.
• People with severe liver or kidney disease.
• People taking multiple prescription medicines where new supplements complicate monitoring.
• Pregnant or breastfeeding people, because routine safety evidence is insufficient.
• Anyone preparing for surgery or a procedure requiring medication/supplement disclosure.

Four different meanings of “drug interaction”

Interaction pages are often misleading because they treat every theoretical overlap as a proven contraindication. In pharmacology, interactions can occur in several ways:

• Pharmacokinetic: one compound changes absorption, metabolism or elimination of another.
• Pharmacodynamic: two interventions push the same physiological outcome, such as blood pressure or glucose.
• Disease-treatment interaction: a supplement changes the biology a treatment is trying to control, as may be relevant during chemotherapy.
• Monitoring interaction: a supplement changes laboratory values or symptoms and makes treatment response harder to interpret.

Most NMN concerns today fall into the last three categories rather than a well-characterized CYP450 interaction table.

Kidney and liver disease

Short human trials do not show a consistent liver-enzyme toxicity signal, and MIB-626 has even been studied under hospital monitoring in people with COVID-19 and acute kidney injury. ^[8]

That does not establish routine safety in advanced chronic kidney or liver disease. Altered clearance, nutrition and polypharmacy make those populations different from healthy-adult supplement trials.

Before surgery and procedures

There is no evidence-based universal rule such as “stop NMN seven days before surgery.” Preoperative teams commonly ask patients to disclose all supplements because fasting, bleeding, glucose control and perioperative medication plans vary.

The correct advice is disclosure rather than inventing a stop interval unsupported by data.

What to bring to a clinician

The useful information is not simply “I take NMN.” Bring the exact product, dose, other supplements, medications and reason for use. A 250 mg verified β-NMN capsule is a different exposure from a multi-ingredient 1,000 mg longevity powder with resveratrol and other actives.

Related NMN guides

• NMN safety
• NMN and cancer
• NMN and diabetes
• NMN and blood pressure
• how to take NMN

Bottom line

NMN has fewer documented drug interactions than many herbal supplements, but the interaction literature is also much thinner. The most responsible position is to separate proven interactions from plausible overlap and genuine unknowns—especially in active cancer treatment and complex medication regimens.